raav2-cb-hrpe65
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00749957)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Retinoid isomerohydrolaseSupplementation
RPE65 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav2-cb-hrpe65
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00749957 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2008 | Applied Genetic Technologies Corp, Oregon Health and Science University, University of Massachusetts |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Genetic Technologies Corp | For profit | 1 | 1 | 1 | 2008 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1